DaVita Inc.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore DaVita
Core profile pages, annual revenue records, and related research hubs for this company.
DaVita Inc.
Compare market positioning with top industry peers
Explore DaVita
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$13.643B
Market Cap
$11.5B
Net Income
$747M
Employees
70,000
DaVita is navigating severe, existential demographic and pharmacological headwinds. Under CEO Javier J. Rodriguez, the kidney dialysis giant generated exactly $12.1 billion in revenue and maintains a $11.5 billion market cap with exactly 70000 employees. The financial narrative in 2026 is defined by extreme structural anxiety; the widespread adoption of GLP-1 weight-loss drugs (which reduce the progression of chronic kidney disease) threatens to permanently shrink DaVita's future patient pipeline. In response, the company is attempting to diversify into broader, value-based integrated kidney care rather than relying solely on high-margin, fee-for-service in-center dialysis treatments.
Revenue Trend Analysis
YoY Change
+6.5%
3-Year CAGR
+5.5%
Peak Year
2025
Trend
Consistent Growth
DaVita Inc. has reported revenue across 4 fiscal years, compounding at +5.5% annually over 3 years. The most recent year saw a 6.5% increase versus the prior year. Revenue peaked in 2025 at $13.6B. Out of 3 reported periods, 3 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $13.6B | $747M | +6.5% |
| FY2024 | $12.8B | $936M | +5.6% |
| FY2023 | $12.1B | $692M | +4.6% |
| FY2022 | $11.6B | $560M | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
DaVita Inc. reported approximately $12.1B in fiscal year 2025 with a team of 70,000 employees worldwide.
DaVita Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Kidney care and dialysis services is driven by steady cash generation and pricing power, enabling DaVita Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "DaVita Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/davita/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>DaVita Inc. reported $14B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/davita/financials" target="_blank" rel="noopener">CorpDigest — DaVita Inc. financials</a></div>